Abstract |
With the emergence of new oral therapies for metastatic melanoma to the market, as well as ongoing pre-marketing trials and special access schemes, it is important to keep up to date with the side effect profiles of these medications. A common side effect associated with the BRAF inhibitor dabrafenib is severe fever symptoms such as pyrexia and rigors/ chills; however, treatment options are limited. We report a patient who was debilitated by severe pyrexia and rigors caused by dabrafenib used in combination with trametinib to treat metastatic melanoma, who was treated with low-dose steroids. To our knowledge, the use of prednisolone for the treatment and prevention of further dabrafenib-associated pyrexia is not published; however, it is a low risk and low cost option that was very effective in this case.
|
Authors | Julian N Lindsay, Michael Barras |
Journal | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
(J Oncol Pharm Pract)
Vol. 21
Issue 4
Pg. 293-5
(Aug 2015)
ISSN: 1477-092X [Electronic] England |
PMID | 24664475
(Publication Type: Case Reports, Journal Article)
|
Copyright | © The Author(s) 2014. |
Chemical References |
- Cephalosporins
- Imidazoles
- Oximes
- Pyridones
- Pyrimidinones
- trametinib
- Cefepime
- dabrafenib
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Cefepime
- Cephalosporins
(therapeutic use)
- Drug Delivery Systems
(adverse effects)
- Female
- Fever
(chemically induced, diagnosis, drug therapy)
- Humans
- Imidazoles
(administration & dosage, adverse effects)
- Melanoma
(diagnosis, drug therapy)
- Oximes
(administration & dosage, adverse effects)
- Pyridones
(administration & dosage, adverse effects)
- Pyrimidinones
(administration & dosage, adverse effects)
- Severity of Illness Index
|